CD106 Antibody / VCAM-1 Antibody

CD106 Antibody Overview

CD106 Antibody reagents target vascular cell adhesion molecule-1 (VCAM-1), a cell-surface glycoprotein belonging to the immunoglobulin superfamily. VCAM-1 is predominantly expressed on activated endothelial cells, where it plays a central role in mediating leukocyte adhesion and transmigration into tissues. Its expression is induced by cytokines such as TNF-α, IL-1β, and IFN-γ, making it a critical component of inflammatory signaling.

VCAM-1 facilitates immune surveillance and response by binding to integrins like VLA-4 (α4β1 integrin) on leukocytes. Dysregulated VCAM-1 expression has been implicated in chronic inflammatory diseases, autoimmune disorders, cardiovascular disease, and cancer metastasis. Because of its broad impact, the CD106 Antibody is a vital tool for immunology, vascular biology, oncology, and translational medicine. The VCAM-1 Antibody supports complementary applications across diagnostics, biomarker studies, and therapeutic development.

Why Choose CD106 Antibodies from NSJ Bioreagents?

NSJ Bioreagents provides CD106 Antibodies validated for immunohistochemistry, flow cytometry, western blotting, immunofluorescence, and ELISA. Each CD106 Antibody undergoes rigorous testing to ensure high specificity, reproducibility, and minimal background.

By choosing CD106 Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and consistency. Our antibodies provide strong staining in endothelial cells, reproducible protein detection in lysates, and robust performance across research platforms. Comprehensive datasheets, validated controls, and optimized protocols further ensure reproducibility in both laboratory and diagnostic workflows.

Applications of CD106 Antibodies

The CD106 Antibody supports diverse applications in research and translational science.

1) Immunology and Inflammation

• CD106 Antibodies detect VCAM-1 upregulation in activated endothelium.

• The CD106 Antibody supports research into leukocyte adhesion and trafficking.

• VCAM-1 Antibody reagents provide insight into chronic inflammation and immune activation.

2) Cardiovascular and Vascular Biology

• CD106 Antibodies highlight VCAM-1 expression in atherosclerotic plaques.

• The CD106 Antibody supports studies of vascular remodeling and endothelial dysfunction.

• VCAM-1 Antibody reagents validate biomarkers for cardiovascular disease.

3) Autoimmunity and Chronic Disease

• CD106 Antibodies detect aberrant VCAM-1 expression in autoimmune disorders.

• The CD106 Antibody supports studies in multiple sclerosis, lupus, and rheumatoid arthritis.

• VCAM-1 Antibody reagents clarify adhesion pathways in chronic inflammatory states.

4) Oncology and Tumor Biology

• CD106 Antibodies identify VCAM-1 expression in tumor vasculature.

• The CD106 Antibody supports cancer metastasis research and biomarker discovery.

• VCAM-1 Antibody reagents provide translational tools for oncology and drug development.

5) Infectious Disease and Host–Pathogen Interactions

• CD106 Antibodies study endothelial activation in bacterial and viral infections.

• The CD106 Antibody supports research into leukocyte recruitment in infectious disease.

• VCAM-1 Antibody reagents contribute to understanding pathogen-driven vascular responses.

6) Translational and Clinical Research

• CD106 Antibodies are applied in biomarker-driven vascular and immunology studies.

• The CD106 Antibody contributes to patient monitoring in clinical trials.

• VCAM-1 Antibody reagents provide reproducibility in translational workflows.

Why Are CD106 Antibodies Important?

VCAM-1 is a key adhesion molecule at the intersection of vascular biology and immune function. The CD106 Antibody provides researchers with validated tools to study endothelial activation, leukocyte trafficking, and inflammation, while the VCAM-1 Antibody extends its use into oncology, cardiovascular biology, and diagnostics.

In immunology, CD106 Antibodies reveal how cytokine-induced endothelial activation drives immune cell migration. In cardiovascular disease, the CD106 Antibody highlights VCAM-1’s role in atherosclerosis and vascular inflammation. In oncology, VCAM-1 Antibody reagents provide insight into tumor vascular biology and metastatic potential.

Clinically, VCAM-1 expression serves as a biomarker and therapeutic target. Antibodies against CD106 are essential for monitoring endothelial responses and evaluating adhesion-blocking therapies.

Conclusion

CD106 (VCAM-1) is a crucial adhesion molecule that regulates leukocyte-endothelial interactions in health and disease. The CD106 Antibody provides scientists and clinicians with validated reagents for studying inflammation, vascular biology, oncology, and autoimmune disorders, while the VCAM-1 Antibody supports broader translational applications in diagnostics and therapy development. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing immunology and improving patient care.